Antithrombin III and Post-liver Transplantation Acute Kidney Injury

Low Preoperative Antithrombin III Level is Associated With Postoperative Acute Kidney Injury After Liver Transplantation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04912193

Enrollment

2395

Registered

2021-06-03

Start date

2010-01-04

Completion date

2019-12-31

Last updated

2021-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation and Antithrombin

Keywords

acute kidney injury, antithrombins, liver transplantation

Brief summary

The reno-protective effect of Antithrombin III (ATIII) has been well-studied in various animal studies; however, little is known about the effect of ATIII on kidney function in patients undergoing liver transplantation (LT). This study aimed to determine the association between preoperative ATIII level and postoperative acute kidney injury (AKI) after LT (post-LT AKI).

Interventions

DRUGAntithrombin III

In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Inclusion criteria

* patients who underwent either living- or deceased-donor LT (LDLT, DDLT) from January 2010 to January 2018

Exclusion criteria

* patients who underwent re-transplantation * patients who were previously diagnosed with end-stage renal disease or Chronic kidney disease * patients who were being treated with continuous renal replacement therapy * preoperative or postoperative Antithrombin III levels were not available

Design outcomes

Primary

Measure	Time frame	Description
acute kidney injury	postoperative 7 day	serum creatinine \>0.3 mg/dL within POD 2 or increase by \>1.5 times within POD 7 according to the criteria set by the Kidney Disease: Improving Global Outcomes (KDIGO) classification

Secondary

Measure	Time frame	Description
chronic kidney disease	postoperative 3 months	glomerular filtration rate less than 60 mL∙min-1∙1.73m-2 on two consecutive occasions at least 3 months apart
early allograft dysfucion	postoperative 7 day	at least one of the following: total bilirubin ≥10 mg/dL on postoperative day (POD) 7, prothrombin time (INR) ≥1.6 on POD 7, and alanine or aspartate aminotransferases \>2000 IU/L within POD 7

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026